PT-141, also known as Bremelanotide, is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts centrally on melanocortin receptors in the brain to enhance sexual arousal and function. Unlike PDE5 inhibitors such as sildenafil (Viagra), PT-141 doesn't work through vascular dilation — it works through the central nervous system, making it effective for both men and women and addressing the psychological component of sexual dysfunction that vasodilators cannot reach.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
PT-141 (Bremelanotide) is used to enhance sexual arousal and function in both men and women. It works centrally through melanocortin receptors in the brain, activating the neural circuits that generate sexual desire. An FDA-approved version (Vyleesi) is approved for hypoactive sexual desire disorder in premenopausal women.
How Does PT-141 Work?
PT-141 is a cyclic heptapeptide derived from Melanotan II that activates melanocortin 3 (MC3R) and melanocortin 4 (MC4R) receptors in the hypothalamus and limbic system. These receptors are part of the neural circuitry governing sexual motivation, arousal, and behaviour.
PDE5 inhibitors like sildenafil work peripherally — they enhance blood flow to erectile tissue but require pre-existing sexual desire to produce a response. PT-141 works upstream: it modulates the neural circuits that generate desire itself. This makes it useful in cases of low libido, hypoactive sexual desire disorder (HSDD), and psychogenic sexual dysfunction where vascular capacity isn't the limiting factor.
An FDA-approved drug based on this mechanism — Vyleesi (bremelanotide injection 1.75 mg) — was approved in 2019 for premenopausal women with hypoactive sexual desire disorder, making PT-141 one of the few research peptides with a direct approved pharmaceutical analog.
Clinical Evidence and FDA Approval Context
The research path to Vyleesi's approval involved multiple Phase 2 and Phase 3 trials. The key Phase 3 trials (RECONNECT program) enrolled over 1,200 premenopausal women with HSDD and demonstrated statistically significant improvements in satisfying sexual events and sexual desire scores compared to placebo.
In men, PT-141 has been studied in erectile dysfunction, including in men who don't respond to PDE5 inhibitors. A Phase 2 trial showed meaningful improvement in erectile function scores in sildenafil non-responders, suggesting that melanocortin pathway stimulation can produce erections through a parallel, PDE5-independent pathway.
Community use in men for recreational enhancement is substantial, with most protocols using lower doses than the 1.75 mg approved for women. The dose-response relationship is meaningful: lower doses (0.5–1 mg) provide arousal enhancement with minimal side effects, while higher doses produce more pronounced effects alongside more significant nausea.
What Is the Recommended PT-141 Dosage?
| Use Case | Dose | Route | Timing | Notes |
|---|---|---|---|---|
| Conservative start | 0.5 mg | SubQ | 1–2 hours before activity | Assess tolerance first |
| Standard (men) | 1–1.5 mg | SubQ | 1–2 hours before activity | Most common protocol |
| Standard (women) | 1.75 mg | SubQ | 45 min before activity | FDA-approved Vyleesi dose |
| Maximum research dose | 2 mg | SubQ | 1–2 hours before activity | Higher nausea risk |
What Are the Side Effects of PT-141?
**Nausea** is the most common and dose-limiting side effect — reported in 40% of women in the Vyleesi trials at 1.75 mg. Nausea typically begins 30–60 minutes post-injection and resolves within 2–4 hours. Lower doses (0.5–1 mg) significantly reduce nausea incidence. Taking with food, staying hydrated, and having anti-nausea medication available is standard harm reduction practice.
**Flushing and hot flashes:** Common within 30–60 minutes of injection. Usually mild and transient. Caused by melanocortin receptor activity in thermoregulatory pathways.
**Transient blood pressure changes:** Bremelanotide caused transient increases in blood pressure in clinical trials, typically peaking at 30 minutes and resolving within 12 hours. The FDA's label warns against use in patients with cardiovascular disease for this reason.
**Hyperpigmentation:** With repeated use, some users notice darkening of skin in injection areas or facial freckling — consistent with melanocortin receptor activity on melanocytes. Less pronounced than with Melanotan II but worth noting.
**Frequency considerations:** Daily use is not recommended. PT-141 appears to show tachyphylaxis (reduced response with frequent dosing). Most protocols use it 1–2 times per week maximum.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
PT-141 (Bremelanotide) is used to enhance sexual arousal and function in both men and women. It works centrally through melanocortin receptors in the brain, activating the neural circuits that generate sexual desire. An FDA-approved version (Vyleesi) is approved for hypoactive sexual desire disorder in premenopausal women. Research protocols use it for low libido, erectile dysfunction (including PDE5 inhibitor non-responders), and sexual enhancement.
Effects typically begin 45–90 minutes after subcutaneous injection and peak around 2–4 hours post-injection. The window of enhanced arousal typically lasts 6–12 hours. Most protocols time injection 1–1.5 hours before intended activity, though individual variation in onset is notable.
They work through fundamentally different mechanisms and aren't directly comparable. Viagra (sildenafil) enhances penile blood flow but requires pre-existing arousal. PT-141 modulates the central desire and arousal pathways — it can generate desire rather than just facilitating the physical response. For men with genuine erectile dysfunction where blood flow is the limiting factor, PDE5 inhibitors may be more reliable. For low libido or psychogenic dysfunction, PT-141 addresses the root issue. Many protocols combine both for synergistic effect.
Yes — the FDA-approved drug Vyleesi is specifically approved for premenopausal women with HSDD at 1.75 mg SubQ. Research protocols for women generally use 0.5–1.75 mg. Women tend to report strong responses at lower doses than men. The nausea side effect appears equally common in both sexes based on clinical trial data.
No more than 1–2 times per week is the typical protocol guidance. More frequent use risks tachyphylaxis (diminishing response) and increases cumulative melanocortin stimulation. The FDA label for Vyleesi recommends no more than once per 24 hours and acknowledges the blood pressure concern with frequent use.
Less than Melanotan II, but some users report mild hyperpigmentation with regular use. PT-141's activity at MC1R (the melanocyte receptor that drives tanning) is much weaker than Melanotan II's. Occasional use for its intended purpose is unlikely to cause noticeable tanning in most skin types.